Baxter Names New President of Renal Business and New Chief Financial Officer

Baxter International Inc. (NYSE:BAX) announced today two executive changes. Robert M. Davis, has been appointed corporate vice president and president of Baxter’s Renal business, filling a role vacated by Bruce H. McGillivray, who is retiring after 30 years of service to the company.

Davis previously served as corporate vice president and chief financial officer for Baxter. Concurrent with this change, Robert J. Hombach has been named corporate vice president and chief financial officer. Hombach previously served as corporate vice president and treasurer for Baxter.

“We are grateful for Bruce’s many contributions over his 30-year career at Baxter,” said Robert L. Parkinson, Jr., chairman and chief executive officer. “Both Rob and Bob have served successfully in a variety of leadership roles, and these new responsibilities further expand the breadth of their expertise.”

Davis has served as chief financial officer since 2006. He joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. He earned his juris doctorate from Northwestern University School of Law and his master's degree from Northwestern University's Kellogg Graduate School of Management, after graduating from Miami University with a bachelor's degree in finance.

Hombach joined Baxter in 1989 and has served in a number of finance positions with increasing responsibility in the planning, manufacturing, operations, and treasury areas. Prior to his role as treasurer, he served as vice president of finance, Europe, and as vice president of corporate planning and analysis, where he led several enterprise-wide initiatives and served as a member of Baxter’s strategy team. Hombach earned his master's degree in business administration from Northwestern University's Kellogg Graduate School of Management, and his bachelor of science degree in finance, cum laude, from the University of Colorado. He has also earned the Certified Public Accountant (CPA) and Certified Management Accountant (CMA) designations.

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

Baxter (NYSE:BAX)
Historical Stock Chart
From Apr 2024 to May 2024